| Description | BMS-191011 (BMS-A) is an activator of large-conductance calcium-activated potassium (BKCa) channels ,effective in stroke models |
| In vivo | In vivo, BMS 191011 (10-100 μg/kg, i.v.) increases the diameter of retinal arterioles without affecting blood pressure or heart rate in rats, an effect that is reversed by the BKCa channel blocker iberiotoxin[1] |
| Synonyms | BMS-A |
| molecular weight | 370.71 |
| Molecular formula | C16H10ClF3N2O3 |
| CAS | 202821-81-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 125 mg/mL (337.19 mM) |
| References | 1. Mori A , Suzuki S , Sakamoto K , et al. BMS-191011, an Opener of Large-Conductance Ca2+-Activated Potassium Channels, Dilates Rat Retinal Arterioles in Vivo[J]. Biological & Pharmaceutical Bulletin, 2011, 34(1):150-152. 2. Hewawasam P . Synthesis of water-soluble prodrugs of BMS-191011: a maxi-K channel opener targeted for post-stroke neuroprotection.[J]. Bioorganic & Medicinal Chemistry Letters, 2003, 13(10):1695-1698. |